In fact, BR55 has been shown to become a tool for predicting and monitoring the response to anti-angiogenic therapy in patients: on the one hand, BR55 can discriminate tumour lesions that are able to respond to therapy with bevacizumab (anti-VEGF monoclonal antibody) and sorafenib (TKI inhibitor of tyrosine kinases, including VEGFR), on the other hand, the method is sensitive to any mutations that the therapy itself induces in the tumour and that may, therefore, emerge during therapeutic treatment [32]. The gene discussed is KDR; the disease is neoplasm.